{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:44:48Z","timestamp":1785282288649,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.05.081","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T11:03:39Z","timestamp":1538046219000},"page":"6867-6874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci"],"prefix":"10.1016","volume":"36","author":[{"given":"Shannon L.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomira","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Liberator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.081_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.05.081_b0010","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe; 2012. Available at: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/Surveillance%20of%20IBD%20in%20Europe%202012.pdf [accessed October 4, 2017]."},{"key":"10.1016\/j.vaccine.2018.05.081_b0015","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease: technical and clinical information. Available at: http:\/\/www.cdc.gov\/meningococcal\/clinical-info.html [accessed October 4, 2017]."},{"issue":"suppl 2","key":"10.1016\/j.vaccine.2018.05.081_b0020","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0025","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3201\/eid2305.161713","article-title":"Meningococci of serogroup X clonal complex 181 in refugee camps, Italy","volume":"23","author":"Stefanelli","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0030","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","article-title":"History of meningococcal vaccines and their serological correlates of protection","volume":"30","author":"Vipond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0035","doi-asserted-by":"crossref","first-page":"20120147","DOI":"10.1098\/rstb.2012.0147","article-title":"The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?","volume":"368","author":"Maiden","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2018.05.081_b0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.05.081_b0045","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report 2016 [2014 data]\u2013 invasive meningococcal disease. Available at: https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2016-2014-data [accessed October 4, 2017]."},{"key":"10.1016\/j.vaccine.2018.05.081_b0050","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.45.30395","article-title":"An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015","volume":"21","author":"Lucidarme","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.05.081_b0055","doi-asserted-by":"crossref","first-page":"e66006","DOI":"10.1371\/journal.pone.0066006","article-title":"Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010\u20132011","volume":"8","author":"Barra","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.05.081_b0060","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3201\/eid2308.170259","article-title":"Clonal expansion of new penicillin-resistant clade of Neisseria meningitidis Serogroup W Clonal Complex 11 Australia","volume":"23","author":"Mowlaboccus","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3201\/eid2307.160129","article-title":"Case-control study of risk factors for meningococcal disease in Chile","volume":"23","author":"Olea","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0070","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.28.21188","article-title":"Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015","volume":"20","author":"Campbell","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.05.081_b0075","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3201\/eid2204.150653","article-title":"Neisseria meningitidis serogroup X in sub-Saharan Africa","volume":"22","author":"Agnememel","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0080","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis, 2013. Available at: http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening13.pdf [accessed October 4, 2017]."},{"key":"10.1016\/j.vaccine.2018.05.081_b0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.14745\/ccdr.v40i09a01","article-title":"Enhanced surveillance of invasive meningococcal disease in Canada, 2006\u20132011","volume":"40","author":"Li","year":"2014","journal-title":"Can Communicable Dis Rep"},{"key":"10.1016\/j.vaccine.2018.05.081_b0090","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33321\/cdi.2016.40.11","article-title":"Summary of national surveillance data on vaccine preventable diseases in Australia, 2008\u20132011","volume":"40","author":"Dey","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2018.05.081_b0095","unstructured":"Lopez L, Sherwood J. Institute of Environmental Science and Research. The epidemiology of meningococcal disease in New Zealand in 2013. Available at: https:\/\/surv.esr.cri.nz\/PDF_surveillance\/MeningococcalDisease\/2013\/2013AnnualRpt.pdf [accessed October 4, 2017]."},{"key":"10.1016\/j.vaccine.2018.05.081_b0100","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.081_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1871526515999150320155614","article-title":"Complications of serogroup B meningococcal disease in survivors: a review","volume":"14","author":"Dastouri","year":"2015","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.vaccine.2018.05.081_b0110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.vaccine.2018.05.081_b0115","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.05.081_b0120","article-title":"A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013","volume":"20","author":"O'Connor","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.05.081_b0125","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1469-0691.2006.01521.x","article-title":"Conventional and molecular investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, Greece","volume":"12","author":"Tzanakaki","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.081_b0130","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0135","unstructured":"Trumenba (MenB-FHbp). Summary of product characteristics. Sandwich, UK: Pfizer Ltd; 2017."},{"key":"10.1016\/j.vaccine.2018.05.081_b0140","unstructured":"Bexsero (MenB-4C). Summary of product characteristics. Siena, Italy: GlaxoSmithKline Vaccines Srl; 2017."},{"key":"10.1016\/j.vaccine.2018.05.081_b0145","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.05.081_b0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.081_b0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.7.0.14564","article-title":"Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease","volume":"7","author":"Harris","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2018.05.081_b0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.081_b0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0185","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0190","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0195","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.05.081_b0200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0205","doi-asserted-by":"crossref","first-page":"e46019","DOI":"10.1371\/journal.pone.0046019","article-title":"Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine","volume":"7","author":"Caugant","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.05.081_b0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/JCM.01447-15","article-title":"Comparison of phenotypic and genotypic approaches to capsule typing Neisseria meningitidis using invasive and carriage isolate collections","volume":"54","author":"Jones","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.081_b0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.081_b0220","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.081_b0225","unstructured":"McNeil L, Zlotnick G, Camposano E, Logan S, Novikova E, Zhao X, et al. Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis. In: 11th EMGM Meeting Ljubljana, Slovenija; 2011. p. 18\u201320."},{"key":"10.1016\/j.vaccine.2018.05.081_b0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.081_b0235","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.081_b0240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.081_b0245","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0140-6736(00)03502-9","article-title":"Serogroup W135 meningococcal disease in Hajj pilgrims","volume":"356","author":"Taha","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.081_b0250","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.12.30175","article-title":"Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016","volume":"21","author":"Campbell","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.05.081_b0255","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","article-title":"Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B C and W lineage","volume":"71","author":"Lucidarme","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.05.081_b0260","doi-asserted-by":"crossref","unstructured":"Ostergaard L, Ward B, Beeslaar J, Eiden J, Jansen KU, Absalon J, et al. Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in young adults: bactericidal activity against a panel of antigenically diverse strains. In: European Society for Paediatric Infectious Diseases; 2016 May 10\u201314; Brighton, UK.","DOI":"10.1093\/ofid\/ofw172.589"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:05:36Z","timestamp":1755716736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":52,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18307473"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}